Anti- cyclic citrullinated peptide antibodies in tuberculosis and human immunodeficiency virus
DOI:
https://doi.org/10.18203/2349-3933.ijam20201615Keywords:
Anti cyclic citrullinated peptide antibody, Human Immunodeficiency Virus, TuberculosisAbstract
Background: Anti-cyclic citrullinated peptide (anti-CCP) antibodies have been considered very specific for rheumatoid arthritis (RA). Some studies have shown that these antibodies can be positive in infectious diseases like tuberculosis, human immunodeficiency virus infection, etc.
Methods: Eighty patients of tuberculosis both pulmonary and extra-pulmonary tuberculosis and thirty patients of human immunodeficiency virus were enrolled in this study from inpatient and outpatient departments from September 2018 to August 2019. Anti-CCP antibody test was done in all the patient by enzyme linked immunosorbent assay.
Results: Fifty-three patients were of pulmonary tuberculosis, 27 patients were extra-pulmonary tuberculosis and 30 patients were human immunodeficiency virus infection. Of the 53 cases of pulmonary tuberculosis, 21 (39.6%) cases were positive for anti-CCP antibodies and 32 (60.4%) cases were negative for the same. Of the 27 cases of extra-pulmonary tuberculosis, 3(11.1%) cases were positive for anti-CCP antibodies and 24 (88.9%) cases were negative. Of the 53 patients of pulmonary tuberculosis, 16 were sputum positive and 37 were sputum negative. Of those with
sputum positive 9 (56.2%) cases were positive for anti-CCP antibodies and those with sputum negative, 12 (32.4%) cases were positive for anti-CCP antibodies. Of the 30 cases of human immunodeficiency virus, 5 (16.7%) cases were positive for anti-CCP antibodies and 25 (83.3%) cases were negative.
Conclusions: Anti-CCP can be positive in cases of infectious diseases like tuberculosis and human immunodeficiency virus. Positivity of anti-CCP antibodies for tuberculosis is more for pulmonary (more for sputum-positive than sputum-negative) than extra-pulmonary tuberculosis. Anti-CCP, thus is not very specific for rheumatoid arthritis.
References
Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101:273-81.
Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays. 2003 Nov;25(11):1106-18.
Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2006;65:845-51.
Lima I, Santiago M. Antibodies against cyclic citrullinated peptides in infectious diseases--a systematic review. Clin Rheumatol 2010;29:1345-51.
Elkayam O, Segal R, Lidgi M, Caspi D. Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis. 2006;65:1110-2.
Londhey V, Shah MM. Anti CCP Antibodies in Tuberculosis. J Associ Physic India. May 2016;(64).
Kakumanu P, Yamagata H, Satoh M. Patients with Pulmonary Tuberculosis are frequently Positive for Anti–Cyclic Citrullinated Peptide Antibodies, but their Sera also React with Unmodified Arginine-Containing Peptide. Arthritis and Rheum. 2008 Jun 1; 58(6):1576-81.
Lima l, Oliveira RC, Atta A, Marchi S, Barbosa L, Reis E, et al. Antibodies to citrullinated peptides in tuberculosis. Clin Rheumatol. 2013;32:685-7.
Whitelaw D, Taljaard JJ, du Plessis LI, Esser M. Lack of specificity of anticyclic citrullinated peptide antibodies in advanced human immunodeficiency virus infection. J Rheumatol. 2011 Jun 1;38(6):1055-60.
Romic Z, Derek L, Burek V, Unic A, Serdar T, Marijancevic D, et al. Anti-cyclic citrullinated peptide and rheumatoid factor in HIV positive patients. Rheumatol Inter. 2011 Dec 1;31(12):1607-10.
Riccio A, Postiglione L, La DP, Spano A, Marzocchella C, Tarantino G. Anti-cyclic citrullinated peptide antibodies in patients affected by HCV-related arthritis. J Biol Regul Homeost Agents. 2008;22(1):57-61.
Bassyouni IH, Ezzat Y, Hamdy S, Talaat RM. Clinical significance of anti-cyclic citrullinated peptide antibodies in Egyptian patients with chronic hepatitis C virus genotype IV infection. Clin Chem Lab Med. 2009;47(7):842-7.
Koga T, Migita K, Miyashita T, Maeda Y, Nakamura M, Abiru S, et al. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with liver diseases. Clin Exp Rheumatol. 2008;26(1):121-4.
Guedes-Barbosa LS, Mangueira C, Scheinberg M. Anticitrulline peptide antibodies (CCP3) in leprosy sera: a negative association. Clin Rheumatol. 2008;27(4):515-6.
Ribeiro SL, Pereira HL, Silva NP, Neves RM, Sato EI. Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in leprosy patients with articular involvement. Braz J Med Biol Res. 2008;41(11);1005-10.
Atta AM, Carvalho EM, Jeronimo SM, Sousa Atta ML. Serum markers of rheumatoid arthritis in visceral leishmaniasis: rheumatoid factor and anti-cyclic citrullinated peptide antibody. J Autoimmun. 2007;28(1):55-8.
